GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (NAS:XRTX) » Definitions » Book Value per Share

XORTX Therapeutics (XORTX Therapeutics) Book Value per Share

: $3.05 (As of Sep. 2023)
View and export this data going back to 2018. Start your Free Trial

XORTX Therapeutics's book value per share for the quarter that ended in Sep. 2023 was $3.05.

During the past 12 months, XORTX Therapeutics's average Book Value Per Share Growth Rate was -43.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of XORTX Therapeutics was 179.70% per year. The lowest was -30.40% per year. And the median was 21.10% per year.

XORTX Therapeutics's current price is $2.9972. Its book value per share for the quarter that ended in Sep. 2023 was $3.05. Hence, today's PB Ratio of XORTX Therapeutics is 0.98.

During the past 8 years, the highest P/B Ratio of XORTX Therapeutics was 63.33. The lowest was 0.00. And the median was 0.00.


XORTX Therapeutics Book Value per Share Historical Data

The historical data trend for XORTX Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => 0.40 [4] => -0.27 [5] => 1.28 [6] => 9.10 [7] => 4.18 )
XORTX Therapeutics Annual Data
Trend Feb15 Feb16 Feb17 Dec18 Dec19 Dec20 Dec21 Dec22
Book Value per Share
Premium Member Only Premium Member Only Premium Member Only 0.40 -0.27 1.28 9.10 4.18

XORTX Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Book Value per Share Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.42 4.18 4.53 3.70 3.05

Competitive Comparison

For the Biotechnology subindustry, XORTX Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XORTX Therapeutics PB Ratio Distribution

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's PB Ratio falls into.



XORTX Therapeutics Book Value per Share Calculation

XORTX Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2022 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(6.98-0.00)/1.67
=4.18

XORTX Therapeutics's Book Value Per Share for the quarter that ended in Sep. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(6.09-0.00)/2.00
=3.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


XORTX Therapeutics  (NAS:XRTX) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


XORTX Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


XORTX Therapeutics (XORTX Therapeutics) Business Description

Traded in Other Exchanges
Address
3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.